Literature DB >> 27103772

Racial Disparities in Creatinine-based Kidney Function Estimates Among HIV-infected Adults.

Naomi Anker1, Rebecca Scherzer2, Carmen Peralta2, Neil Powe2, Tanushree Banjeree2, Michael Shlipak1.   

Abstract

OBJECTIVE: The aim of our study was to investigate whether current eGFR equations in clinical use might systematically over-estimate the kidney function, and thus misclassify CKD status, of Black Americans with HIV. Specifically, we evaluated the impact of removing the race coefficient from the MDRD and CKD-EPI equations on comparisons between Black and White HIV-infected veterans related to: 1) the prevalence of reduced eGFR; 2) the distribution of eGFR values; and 3) the relationship between eGFR and all-cause mortality.
DESIGN: Retrospective cohort study.
SETTING: The Department of Veterans Affairs (VA) HIV Clinical Case Registry (CCR), which actively monitors all HIV-infected persons receiving care in the VA nationally. PATIENT/PARTICIPANTS: 21,905 treatment-naïve HIV-infected veterans. MAIN OUTCOME MEASURES: Estimated glomerular filtration rate (eGFR) using the abbreviated Modification of Diet in Renal Disease (MDRD) formula with and without (MDRD-RCR) the race coefficient and all-cause mortality.
RESULTS: Persons with eGFR <45 mL/min/1.73m(2) had a higher risk of death compared with those with eGFR >80 mL/min/1.73m(2) among both Blacks (HR=2.8, 95%CI: 2.4-3.3) and Whites (HR=1.9, 95%CI: 1.4-2.6), but the association appeared to be stronger in Blacks (P=.038, test for interaction). Blacks with eGFR 45-60 mL/min/1.73m(2) also had a higher risk of death (HR=1.7, 95%CI: 1.4-2.1) but Whites did not (HR=.86, 95%CI: .67-1.10; test for interaction: P<.0001). Racial differences were substantially attenuated when eGFR was re-calculated without the race coefficient.
CONCLUSIONS: Our findings suggest that clinicians may want to consider estimating glomerular filtration rate without the race coefficient in Blacks with HIV.

Entities:  

Keywords:  Chronic Kidney Disease; Estimated Glomerular Filtration Rate; Human Immunodeficiency Virus; Mortality; Racial Disparities

Mesh:

Substances:

Year:  2016        PMID: 27103772      PMCID: PMC4836902          DOI: 10.18865/ed.26.2.213

Source DB:  PubMed          Journal:  Ethn Dis        ISSN: 1049-510X            Impact factor:   1.847


  34 in total

1.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

2.  Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.

Authors:  Eric C Seaberg; Alvaro Muñoz; Ming Lu; Roger Detels; Joseph B Margolick; Sharon A Riddler; Carolyn M Williams; John P Phair
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

3.  Predictors of proteinuria and renal failure among women with HIV infection.

Authors:  Lynda Anne Szczech; Stephen J Gange; Charles van der Horst; John A Bartlett; Mary Young; Mardge H Cohen; Kathryn Anastos; Preston S Klassen; Laura P Svetkey
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population.

Authors:  Katherine Barraclough; Lee Er; Francisco Ng; Marianne Harris; Julio Montaner; Adeera Levin
Journal:  Nephron Clin Pract       Date:  2008-12-03

6.  Microalbuminuria in HIV infection.

Authors:  Lynda Anne Szczech; Carl Grunfeld; Rebecca Scherzer; Jesse A Canchola; Charles van der Horst; Stephen Sidney; David Wohl; Michael G Shlipak
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

7.  The impact of HIV on chronic kidney disease outcomes.

Authors:  A I Choi; R A Rodriguez; P Bacchetti; D Bertenthal; P A Volberding; A M O'Hare
Journal:  Kidney Int       Date:  2007-09-05       Impact factor: 10.612

8.  Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races.

Authors:  Gregory M Lucas; Bryan Lau; Mohamed G Atta; Derek M Fine; Jeanne Keruly; Richard D Moore
Journal:  J Infect Dis       Date:  2008-06-01       Impact factor: 5.226

9.  Cystatin C as a risk factor for outcomes in chronic kidney disease.

Authors:  Vandana Menon; Michael G Shlipak; Xuelei Wang; Josef Coresh; Tom Greene; Lesley Stevens; John W Kusek; Gerald J Beck; Allan J Collins; Andrew S Levey; Mark J Sarnak
Journal:  Ann Intern Med       Date:  2007-07-03       Impact factor: 25.391

10.  Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Authors:  Stephane De Wit; Caroline A Sabin; Rainer Weber; Signe Westring Worm; Peter Reiss; Charles Cazanave; Wafaa El-Sadr; Antonella d'Arminio Monforte; Eric Fontas; Matthew G Law; Nina Friis-Møller; Andrew Phillips
Journal:  Diabetes Care       Date:  2008-02-11       Impact factor: 17.152

View more
  2 in total

Review 1.  The global burden of chronic kidney disease: estimates, variability and pitfalls.

Authors:  Richard J Glassock; David G Warnock; Pierre Delanaye
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

2.  Estimated glomerular filtration rate equations in people of self-reported black ethnicity in the United Kingdom: Inappropriate adjustment for ethnicity may lead to reduced access to care.

Authors:  Rouvick M Gama; Amanda Clery; Kathryn Griffiths; Neil Heraghty; Adrien M Peters; Kieran Palmer; Henry Kibble; Royce P Vincent; Claire C Sharpe; Hugh Cairns; Kate Bramham
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.